Figure 5.

AKT1 mutation analysis. A: Illustration of the AKT1 protein domains and AKT1 mutations observed in the patients with diffuse large B-cell lymphoma (DLBCL). B and C: Among patients with high levels of phosphorylated AKT (p-AKT^high), patients with AKT1 mutations (MUT) tend to have poorer progression-free survival than patients with wild-type (WT) AKT1 in the overall DLBCL cohort (B) and in the germinal center B-cell–like (GCB) subgroup (C). ABC, activated B-cell–like; PH, pleckstrin homology; UC, unclassifiable.